KP 692

Drug Profile

KP 692

Alternative Names: FFC 14a; KP 1019; NSC 666158

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Heidelberg
  • Developer Faustus Forschungs Compagnie; University of Heidelberg
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Austria (IV-infusion)
  • 29 May 2009 Phase I development is ongoing
  • 01 Dec 2005 Phase-I clinical trials in Solid tumours in Austria (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top